An observational study in Colonic Neoplasms and Cryptosporidiosis, sponsored by Lille Catholic University. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Lille Catholic University · Observational
No other patients could be included within the time frame.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Colonic Neoplasms with a site in France — 49 open to participants now, 66 under way, 13 of them phase 3. Colonic Neoplasms · France.
Among the 213 studies in Colonic Neoplasms with a site in France, this one has the largest enrollment of the 55 observational ones that give a count, is one of 11 that started in 2020, is one of 55 observational ones, and was the 142nd registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →49 of the 213 studies in Colonic Neoplasms with a site in France are open now. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Incyte Corporation · Sites in France, United States, Argentina and 19 more countries
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Spain
Ages 18+
Pfizer · Sites in France, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 56 · Phase 3 44 · Phase 4 3
First in 1990; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 324,117 is above the median of 227 across 555 observational studies indexed under Colonic Neoplasms.
Median enrollment 186 across the 143 interventional studies, 220 across the 55 observational. Of the 106 that completed or were terminated, 20 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 213 have an industry lead sponsor. The 10 most frequent:
Lille Catholic University is the lead sponsor of 112 studies on the registry; 24 are open to participants now.
Lille Catholic University has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Colonic Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07000474University Hospital, BrestMultiparametric Characterization of Colorectal Cancers (METRAD) | 2026-12-31 |
| NCT05433142Xencor, Inc.Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | 2027-02 |
| NCT05577143University Hospital, LilleBlood Screening for Adult Colorectal Cancer | 2027-03 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT06287814University Hospital, MontpellierFrench Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) | 2027-04-11 |
Add all 10 to your calendar (.ics) → With an account.
Among the 213 studies in Colonic Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It has been reported that Cryptosporidium parvum, a species of a protozoan frequently isolated from humans and animals, is able to induce digestive adenocarcinoma in a rodent model. Consistently, some epidemiological studies have reported an association with cryptosporidiosis in patients with colorectal adenocarcinoma. However, the correlation between cryptosporidiosis and human digestive cancer remains unclear at this time, and it is not known whether this intracellular parasite, considered an opportunistic agent, is able to induce gastrointestinal malignancies in humans. In order to add new arguments for a probable association between cryptosporidiosis and digestive human cancer, the main aim of this study is to determine prevalence and to identify species of Cryptosporidium among a French digestive cancer population.
The cases will be the patients with colon cancer of recent diagnosis recruited in consultation either in the surgical or gastroenterology departments. The controls will be the patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure and recruited either in the surgical or gastroenterology departments
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cases:
Controls:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with colon cancer of recent diagnosis will be recruited in consultation either in the surgical or gastroenterology departments
Diagnostic Test: Detection of Cryptosporidium infection
Patients without colon cancer but with other gastrointestinal pathology needing a biopsy or a surgical procedure will be recruited either in the surgical or gastroenterology departments
Diagnostic Test: Detection of Cryptosporidium infection
A biopsy or a surgical sample will be collected from every participant
Prevalence of Cryptosporidium
A biopsy or a surgical sample will be collected from every participant which will be then screened for Cryptosporidium using a Polymerase chain reaction (PCR) in order to obtain a prevalence of positive individuals
Time frame: 3 years
Rate of occurrence of parasite development in the tumoral zone (yes/no) compared to the peri-tumoral zone.
A biopsy or a surgical sample containing the tumoral and peri-tumoral areas will be collected only from the cases which will be then screened for Cryptosporidium using PCR
Time frame: 3 years
Significance of the association between the histological grade of the lesion and the Cryptosporidium species
Significance of the association between the histological grade defined by the Vienna classification of tumors and the species of Cryptosporidium and the Cryptosporidium species.The main species of Cryptosporidium infecting humans are C. parvum and C. hominis, however, other species can also infect humans.
Time frame: 3 years
Significance of the association between the histological grade of the lesion and the parasitic charge in tissues
Significance of the association between the histological grade defined by the Vienna classification of tumors and the species of Cryptosporidium and the parasitic charge in the tissues that will be determined by quantitative polymerase chain reaction (qPCR)
Time frame: 3 years
The rate of change in the expression or localization of certain markers known or suspected to be involved in the process of carcinogenesis.
Some markers known to be associated to cancer development will be explored such as: Beta-catenin, P53, APC (adenomatous polyposis coli), etc.
Time frame: 3years
The association between the rate of lymphocytes (CD3, CD4, CD8, CD19 and CD4/CD8 ratio) and the presence of parasites in biopsies or surgical specimens
Because Cryptosporidium is an opportunistic agent that causes significant morbidity and mortality in immunocompromised patients, it is possible that individuals with malignancies, have a higher risk of developing infection with this parasite, especially when their immunosuppression is more severe. To rule out this possibility this association will be determined.
Time frame: 3 years
Rate of development of a neoplastic lesion in the human explants
A three-dimensional culture model will be developed using colon samples from healthy tissues of several control patients. An experimental Cryptosporidium infection will be tested in order to determine the development of neoplastic lesions in these human explants.
Time frame: 3 years
Ran from Jun 2020 to primary completion in Jun 2025, 59 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jun 2024 → Jun 2025 and completion Dec 2024 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
No other patients could be included within the time frame.
No other patients could be included within the time frame.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.